Milestone Alert: First Subject Dosed in Phase 2b Vitiligo Trial of Novel BET Inhibitor
The first person has been dosed in a Phase 2b trial evaluating Vyne’s VYN201 in subjects with either active or stable nonsegmental vitiligo. VYN201 is a novel pan-bromodomain and extra-terminal domain (BET) inhibitor designed for local administration. Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. Check out TDD’s one-on-one interview with […]